Stock A003520 YUNGJIN PHARM. CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Yungjin Pharm. Co., Ltd. Share Price

Equities

A003520

KR7003520004

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 25/06/2024 BST 		5-day change 1st Jan Change
2,125 KRW -1.39% Intraday chart for Yungjin Pharm. Co., Ltd. -3.19% 0.00%
2023 Yungjin Pharm. Co., Ltd. announced that it has received KRW 30.3 billion in funding from a group of investors CI
2023 Yungjin Pharm. Co., Ltd. announced that it expects to receive KRW 30.3 billion in funding from a group of investors CI

Financials

Sales 2008 111B 79.82M 6.32B Sales 2009 103B 74.43M 5.9B Capitalization 145B 105M 8.3B
Net income 2008 -6.73B -4.85M -384M Net income 2009 -4.35B -3.13M -248M EV / Sales 2008 1.15 x
Net Debt 2008 34.9B 25.13M 1.99B Net Debt 2009 46.26B 33.31M 2.64B EV / Sales 2009 1.85 x
P/E ratio 2008
-13.7 x
P/E ratio 2009
-33.5 x
Employees 574
Yield 2008 *
-
Yield 2009
-
Free-Float 47.54%
More Fundamentals * Assessed data

Chart Yungjin Pharm. Co., Ltd.

Dynamic Chart

Latest news about Yungjin Pharm. Co., Ltd.

Yungjin Pharm. Co., Ltd. announced that it has received KRW 30.3 billion in funding from a group of investors CI
Yungjin Pharm. Co., Ltd. announced that it expects to receive KRW 30.3 billion in funding from a group of investors CI
Yungjin Pharm. Co., Ltd.(KOSE:A003520) dropped from KOSPI 200 Index CI
Neurovive and Yungjin Report Positive KL1333 Phase I Clinical Study Results Paving the Way for Further Clinical Development CI
Neurovive Pharmaceutical AB and Yungjin Pharm Corporation Ltd Completes the Clinical Phase I Single Ascending Dose Study of KL1333 CI
NeuroVive Pharmaceutical AB and Yungjin Pharm Report Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333 CI
LG Ro Local Housing Association completed the acquisition of land and buildings at 2034 Gyeonggidae-ro, Jinwi-myeon, Pyeongtaek-si, Gyeonggi-do, South Korea from Yungjin Pharm. Co., Ltd.. CI
NeuroVive Pharmaceutical AB and Yungjin Pharm Corporation Ltd Announce Clinical Phase I Study of KL1333 CI
Neurovive Pharmaceutical AB and Yungjin Pharm Corporation Ltd Enters into Global Licensing Agreement on Yungjin Pharm's Compound KL333 CI
Yungjin Pharm. Co., Ltd. completed the acquisition of KT&G Life Sciences. CI
LG Ro Local Housing Association signed a contract to acquire land and buildings at 2034 Gyeonggidae-ro, Jinwi-myeon, Pyeongtaek-si, Gyeonggi-do, South Korea from Yungjin Pharm. Co., Ltd. for KRW 21.4 billion. CI
Yungjin Pharm. Co., Ltd. agreed to acquire KT&G Life Sciences for KRW 87.4 billion. CI
Yungjin Pharm. Co., Ltd.(KOSE:A003520) dropped from Russell Global Index CI
Haitai Beverage Co., Ltd. completed the acquisition of the assets of drink business unit from Yungjin Pharm. Co., Ltd.. CI
Haitai Beverage Co., Ltd. agreed to acquire the assets of drink business unit from Yungjin Pharm. Co., Ltd. for KRW 7.1 billion. CI
More news

Press releases Yungjin Pharm. Co., Ltd.

Yungjin Pharm : signed a collaborative research agreement with Curome for treatment of rare mitochondrial disease PU
Yungjin Pharm : Abliva announces positive clinical phase 1a/b results in PMD patients for KL1333 that has been in-licensed from Yungjin PU
Yungjin Pharm : Family-Friendly certification proves that Yungjin Pharmaceutical is a great place to work PU
More press releases

Quotes and Performance

1 day-1.39%
1 week-3.19%
Current month+3.66%
1 month+3.16%
3 months-2.07%
6 months+2.41%
More quotes

Highs and lows

1 week
2 110.00
Extreme 2110
2 230.00
1 month
2 025.00
Extreme 2025
2 335.00
Current year
1 950.00
Extreme 1950
2 335.00
1 year
1 950.00
Extreme 1950
2 995.00
3 years
1 950.00
Extreme 1950
6 150.00
5 years
1 950.00
Extreme 1950
12 800.00
10 years
1 255.00
Extreme 1255
19 200.00
More quotes

Managers and Directors - Yungjin Pharm. Co., Ltd.

Managers TitleAgeSince
Gi-Soo Lee CEO
 Chief Executive Officer 58 23/03/22
Hyo-Jin Oh BRD
 Director/Board Member 52 -
Members of the board TitleAgeSince
Chang-Joon Song BRD
 Director/Board Member 54 23/03/17
Hyo-Jin Oh BRD
 Director/Board Member 52 -
Gi-Soo Lee CEO
 Chief Executive Officer 58 23/03/22
More insiders

ETFs positioned on Yungjin Pharm. Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.00% 4 M€ -4.41% -
More ETFs positioned on Yungjin Pharm. Co., Ltd.

Quotes

Date Price Change Volume
26/06/24 2,125 -1.39% 137,633
25/06/24 2,155 +0.94% 202,301
24/06/24 2,135 -1.16% 247,531
21/06/24 2,160 -1.82% 184,418
20/06/24 2,200 +0.23% 178,958

End-of-day quote Korea S.E., June 25, 2024

More quotes

Company Profile

Yungjin Pharma Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of pharmaceutical products. The Company mainly manufactures and sells pharmaceutical products including antibiotics, respiratory drugs, anti-infective drugs, antipyretics, analgesics, central nervous system (CNS) drugs, gastrointestinal (GI) drugs, cardiovascular (CV) drugs, antihistamines, antifungals, antidiabetics, vitamin nutrients, antibiotic raw materials, and others. The Company also engages in the leasing of real estates.
Sector
Pharmaceuticals
Calendar
12/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
YUNGJIN PHARM. CO., LTD. Stock Yungjin Pharm. Co., Ltd.
0.00% 279M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.61% 811B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.25% 640B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.62% 333B
ABBVIE INC. Stock AbbVie Inc.
+10.44% 302B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 246B
ROCHE HOLDING AG Stock Roche Holding AG
+2.09% 225B
NOVARTIS AG Stock Novartis AG
+13.03% 218B
AMGEN INC. Stock Amgen Inc.
+8.61% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A003520 Stock